Subscribe
Be the first with the news that moves the market- Reliq Health Technologies (RHT) has secured a new contract with a large U.S. health plan
- The client operates accountable care organizations in five states with over 3,000 doctors and more than 1,000,000 patients
- The initial 10,000 patients will be onboarded by March 2024 at an average revenue of $65 per patient per month
- Reliq Health Technologies is a healthcare technology company specializing in virtual care solutions
- Reliq Health Technologies (RHT) last traded at $0.61 per share
Reliq Health Technologies (RHT) has secured a new contract with a large U.S. health plan.
The health plan is a subsidiary of one of the nation’s largest providers of hospital and healthcare services and a Fortune 500 company. It operates accountable care organizations (ACOs) in five states with over 3,000 doctors and more than 1,000,000 patients.
ACOs are groups of healthcare providers that work under a value-based care model to reduce healthcare costs and improve quality of care.
Onboarding begins in July with an ACO in Texas, which will add over 10,000 new patients to Reliq’s iUGO Care platform by March 2024. Reliq expects average revenue of $65 per patient per month at a 75-per-cent gross margin.
The remote patient monitoring, chronic care management and behavioral health integration solutions provided through iUGO will assist the ACOs in achieving their cost and quality of care objectives.
“We are very pleased to have signed our first contract with a U.S. health plan,” stated Lisa Crossley, Reliq’s CEO. “This new contract is further validation of Reliq’s unique value proposition in the U.S. healthcare market and clearly demonstrates our rapidly accelerating traction with large, multi-state U.S. healthcare organizations.”
Reliq Health Technologies is a healthcare technology company specializing in virtual care solutions.
Reliq Health Technologies (RHT) last traded at $0.61 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
